Search the Newsreel

Does Strong Q1 Results And VASCADE Data Shift The Bull Case For Haemonetics (HAE)?

Haemonetics Corporation reported stronger-than-expected Q1 results with increased sales and diluted EPS, along with positive new Emory University study data reinforcing the safety and efficiency of its VASCADE MVP XL venous vascular closure system. These developments, particularly the VASCADE data, are seen as significant …

Haemonetics stock hits 52-week high at 88.73 USD

Haemonetics Corp's stock reached a new 52-week high of $88.73, marking a significant 67.34% increase over the past year and reflecting strong investor confidence. The medical technology company's market capitalization stands at $3.97 billion, with its P/E ratio of 42 suggesting it may be …

Haemonetics (HAE) Reliance on International Sales: What Investors Need to Know

Have you looked into how Haemonetics (HAE) performed internationally during the quarter ending June 2026? Considering the widespread global presence of this provider blood management systems for health care providers and blood collectors, examining the trends in international revenues is essential for assessing its …

Renaissance Technologies LLC Takes $2.44 Million Position in Haemonetics Corporation $HAE

Renaissance Technologies LLC has acquired a new position in Haemonetics Corporation, purchasing 43,200 shares valued at approximately $2.44 million. Haemonetics maintains a "Moderate Buy" consensus rating from analysts, with an average price target of $90.89, following strong quarterly earnings that surpassed expectations. Institutional investors …

Weyerhaeuser Co. stock underperforms Monday when compared to competitors

Weyerhaeuser Co. (WY) stock fell 1.13% on Monday, closing at $25.29, despite an overall dismal trading session where the S&P 500 and Dow Jones Industrial Average also saw slight declines. The company's stock is now 8.86% below its 52-week high reached in February. This …

Michael Hill (ASX:MHJ): Earnings Recovery Gains Support From Sales Growth Across Markets

Haemonetics Corporation (HAE) Stock forecasts

Argus has raised its target price for Haemonetics Corporation (HAE) stock to $90.00. The company, currently trading at $86.61, focuses on improving patient care and reducing healthcare costs through its medical products and solutions for blood and plasma collection, surgical suites, and hospital transfusion …

Is Haemonetics (HAE) Undervalued As Q1 Earnings And Outlook Lift Optimism?

Janus Henderson Group PLC Has $2.57 Million Holdings in Weyerhaeuser Company $WY

Janus Henderson Group PLC significantly reduced its stake in Weyerhaeuser Company by 75.1% in the first quarter, selling over 316,000 shares but still retaining holdings valued at approximately $2.57 million. Weyerhaeuser exceeded Q1 earnings estimates with an EPS of $0.13 and reported revenue of …

Trading Systems Reacting to (WY) Volatility

This article analyzes Weyerhaeuser Company (NYSE: WY) volatility using AI models to generate trading strategies. It highlights a strong near-term sentiment, a mid-channel oscillation pattern, and an exceptional risk-reward short setup. The analysis provides specific entry, target, and stop-loss levels for position, momentum breakout, …

Weyerhaeuser (WY) Could Be 18% Undervalued On Its Latest Earnings Beat

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Weyerhaeuser (WY) is back in focus after reporting second quarter 2026 net income of …

Weyerhaeuser (WY) Stock Looks Cheap On Cash Flow But Pricey On Earnings

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Weyerhaeuser stock has delivered a decline of about 15.1% over the past three years, yet current valuation checks suggest the shares now sit …

Haemonetics Q1 Earnings Call Highlights

Key Points Interested in Haemonetics Corporation? Here are five stocks we like better. Haemonetics raised its fiscal 2027 outlook, now expecting reported revenue growth of 5%–8% and organic growth of 4%–7%, after first-quarter revenue increased 6% to $339 million and adjusted EPS rose 4% …

Weyerhaeuser (WY) Could Be 18% Undervalued After Stronger Second Quarter Earnings

Weyerhaeuser (WY) recently reported strong second-quarter 2026 earnings, with net income of US$162 million and earnings per share of US$0.23, leading to short-term stock gains. Despite these positive developments, Simply Wall St suggests the stock could still be 18% undervalued, with a fair value …

Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen has upgraded Haemonetics (NYSE:HAE) to a "strong-buy" rating, reflecting positive analyst sentiment and strong financial performance. The company exceeded quarterly expectations with $1.14 EPS and $339.38 million in revenue, leading management to raise its fiscal 2027 revenue-growth outlook to 5%-8%. Haemonetics' …

Haemonetics (HAE) Stock Extends Run As Cash Flow Strength Meets Margin Pressure

Weyerhaeuser (WY) Q2 2026 Earnings Call Transcript

WY Q2 Beat Shows a Lumber Rebound but Higher OSB Costs Cloud Outlook

Weyerhaeuser (WY) reported a stronger-than-expected Q2 earnings beat, driven by improvements in lumber and engineered wood products. However, the recovery was not broad-based, with higher oriented strand board (OSB) costs and weaker contributions from other segments impacting the overall outlook. The company's Q3 guidance …

WY Stock Jumps 13.1% in a Month: Can the Rally Keep Gaining Ground?

Weyerhaeuser Company WY shares have gained 13.1% in the past four weeks, putting the durability of the move in focus. The advance has coincided with a second-quarter 2026 earnings beat and a sequential recovery in Wood Products. The setup is not one-directional. Housing remains …

HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $95 FROM $89

Barrington Research has increased its target price for Haemonetics Corp (HAE.N) to $95 from $89. This adjustment reflects an updated valuation for the company. The article cites Reuters as the source of this information.

Earnings call transcript: Haemonetics beats Q1 2026 estimates, stock slips premarket

Haemonetics (HAE) reported stronger-than-expected fiscal first-quarter results, with adjusted EPS of $1.14 on revenue of $339 million, exceeding analyst estimates. Despite the beat and raised full-year revenue guidance, the stock declined 1.91% in premarket trading, indicating investor focus on the company's cautious outlook and …

Weyerhaeuser Company (NYSE:WY) Given Consensus Rating of "Moderate Buy" by Brokerages

Weyerhaeuser Company (NYSE:WY) has received a "Moderate Buy" consensus rating from eleven brokerages, with an average 12-month price target of $29.00. The company recently reported Q2 earnings of $0.13 EPS on $1.87 billion revenue, exceeding analyst estimates despite an 8.3% year-over-year revenue decline. Weyerhaeuser …

Haemonetics Corp (HAE) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Haemonetics Corp (HAE), detailing its current price momentum score of 4.19 and its trading range between a resistance level of $91.33 and a support level of $75.97. It evaluates various technical indicators, including MACD, RSI, and moving …

HAEMONETICS CORP 2026: Revenue $339.38M, EPS $0.72— 10-Q Summary

HAEMONETICS CORP reported strong financial results for the 2026 quarter, with revenue increasing by 5.6% year-over-year to $339.38 million. Diluted EPS also saw a rise to $0.72. The company attributed its revenue growth to expanded Apheresis plasma volume and market share gains in its …

Haemonetics (NYSE: HAE) grows revenue 5.6% in Q1 2027

Haemonetics Corporation (NYSE: HAE) reported a 5.6% increase in net revenues for Q1 fiscal 2027, reaching $339.38 million. Operating income grew by 6.7% to $57.46 million, while diluted EPS rose 2.9% to $0.72. The company also detailed its segment reorganization into Apheresis and MedSurg, …

Haemonetics Corporation 2027 Q1 - Results - Earnings Call Presentation (NYSE:HAE) 2026-08-06

BTIG raises Haemonetics stock price target to $96 on strong results

BTIG has increased its price target for Haemonetics Corp. (NYSE:HAE) to $96 from $84, maintaining a Buy rating after the company reported strong first-quarter revenues and adjusted earnings per share that surpassed consensus estimates. All segments performed well, with Interventional Technologies returning to growth …

Haemonetics (HAE) Tops Q1 Earnings and Revenue Estimates

Haemonetics (HAE) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $1.07 per share. This compares to earnings of $1.1 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations

Haemonetics (NYSE:HAE) Beats Q2 CY2026 Sales Expectations Blood products company Haemonetics (NYSE:HAE) reported Q2 CY2026 results beating Wall Street's revenue expectations , with sales up 5.6% year on year to $339.4 million. Its non-GAAP profit of $1.14 per share was 5.8% above analysts' consensus …

Haemonetics Corporation Announces First Quarter Fiscal 2027 Financial Results Available on Investor Relations Website

Haemonetics Corporation announced that its first quarter fiscal year 2027 financial results, for the period ending June 27, 2026, are now available on its Investor Relations website. The company will also host a conference call and webcast on August 6, 2026, at 8:00 a.m. …

Haemonetics sets Aug. 6 webcast to discuss fiscal Q1 results

Haemonetics (NYSE: HAE) announced that its financial results for the first quarter of fiscal 2027, which ended June 27, 2026, are now available on its Investor Relations website. The company will host an investor conference call and live webcast on August 6, 2026, at …

Haemonetics Reports Q1 FY2027: Revenue $339.4M, Adjusted EPS $1.14, Raises FY27 Guidance

Haemonetics announced its first-quarter fiscal 2027 results, reporting net revenue of $339.4 million, a 5.6% year-over-year increase, and adjusted earnings per diluted share of $1.14. The company raised its full-year fiscal 2027 revenue and organic growth targets, attributing the strong performance to plasma share …

The Bull Case For Weyerhaeuser (WY) Could Change Following Sharply Higher First-Half 2026 Profitability

Weyerhaeuser (WY) reported a significant increase in net income for the second quarter and first half of 2026, with Q2 net income rising to US$162 million and first-half net income almost doubling to US$318 million. This improved profitability strengthens the company's near-term earnings picture …

Haemonetics (HAE) Earnings Date and Reports 2026 $HAE

Weyerhaeuser Company Stock: Is Wall Street Bullish or Bearish?

Weyerhaeuser Raymond Lumber site with logo By IanDewarPhotography Weyerhaeuser Company (WY) is one of the world's largest private owners of timberlands and a leading real estate investment trust (REIT) focused on sustainable forest management and wood products manufacturing. Weyerhaeuser produces a wide range of …

Weyerhaeuser Earnings Call Balances Growth With Headwinds

Weyerhaeuser (WY) reported Q2 earnings, showcasing resilient profitability despite market headwinds. The company emphasized strong cash generation, improved lumber fundamentals, and disciplined capital allocation, even while acknowledging pressures from OSB markets, transportation issues, and softer housing demand. Growth initiatives in renewables and engineered wood …